Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK1 Y654F JAK3 A573V |
Therapy | Ruxolitinib |
Indication/Tumor Type | Sezary's disease |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK1 Y654F JAK3 A573V | Sezary's disease | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited growth of a Sezary syndrome cell line harboring JAK1 Y654F and JAK3 A573V in culture (PMID: 26415585). | 26415585 |
PubMed Id | Reference Title | Details |
---|---|---|
(26415585) | Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. | Full reference... |